SANOFI SA INHABER EO 2/ FR0000120578 /
8/28/2024 9:43:26 PM | Chg. -0.040 | Volume | Bid8/28/2024 | Ask8/28/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
100.540EUR | -0.04% | 1,297 Turnover: 130,293.100 |
100.340Bid Size: 99 | 100.840Ask Size: 99 | 126.59 bill.EUR | 3.72% | 23.43 |
Newsfile Corp
8/28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
8/14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
8/13
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/12
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
8/8
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
8/7
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
8/6
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
8/1
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
7/31
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
7/25
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
7/25
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
7/24
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
7/18
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...
GlobeNewswire
7/17
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...
GlobeNewswire
7/12
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...
GlobeNewswire
7/11
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...
GlobeNewswire
7/8
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...